FOR US HEALTHCARE PROFESSIONALS ONLY
FOR US HEALTHCARE PROFESSIONALS ONLY
Go to Patient/Caregiver Site
Instructions for Use Prescribing Information Chiesi Total Care Go to Patient/Caregiver Site
FILSUVEZ logo
Request a Rep Butterflies
Req form internal hero background Req form internal hero mobile background

Request a rep

To request a rep, please fill in the information below.

I don't have an NPI
By completing this form, I am providing consent to Chiesi USA, Inc. to process and retain my personal data for the purposes of receiving information and updates on FILSUVEZ. I also confirm that I have read and agree to the terms of the Privacy Policy located at www.chiesiusa.com/privacy. To opt-out of this use of your personal data, you may submit a request via our Privacy Center (depending on your State of residence), email us.privacy@chiesi.com or contact us via phone at 1-866-271-8587.*
For California residents: You may also view Chiesi USA, Inc.'s California Notice at Collection at www.chiesiusa.com/privacy.
* Required fields.

Thanks

Thank you for requesting a rep! A confirmation email has been sent to your inbox.

Important Safety Information & Indication

Important Safety Information & Indication

Important Safety Information

Warnings & Precautions

Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.

Adverse Reactions

The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).

Patient Counseling Information

Please refer to Prescribing Information for administration instructions.

To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Indication

FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.
PP-RA-02243 V1.0